Sakar Healthcare Q4 FY26 Results: PAT Rs 11.02 Crore Up 91.32 Percent YoY Revenue Rs 71.10 Crore Operating Margin 36.91 Percent

Sakar Healthcare Q4 FY26 results were announced on 12 May 2026, with the Ahmedabad-based specialty pharmaceutical company reporting a consolidated net profit of Rs 11.02 crore for the quarter ended March 31, 2026, a robust 91.32 percent year-on-year surge from the year-ago period. Sakar Healthcare Q4 FY26 revenue climbed to Rs 71.10 crore, a 41.52 percent year-on-year expansion, with a modest 1.08 percent sequential gain. Most impressively, the company achieved its highest-ever quarterly operating margin (excluding other income) of 36.91 percent in Q4 FY26, a 560 basis point expansion from the previous quarter and an equivalent improvement year-on-year. The stock responded positively, gaining 4.94 percent to close at Rs 597.80 on 13 May 2026.

Click Here – Get Free Investment Predictions

Sakar Healthcare Q4 FY26 Key Financial Highlights

Parameter	Q4 FY26	Reference
Net Profit (PAT)	Rs 11.02 crore	+91.32% YoY
Revenue from Operations	Rs 71.10 crore	+41.52% YoY
Operating Margin	36.91%	Highest ever; +560 bps QoQ
PAT Margin	15.50%	+4.04 percentage points YoY
Stock Reaction	+4.94% on May 13	Closed at Rs 597.80
Market Cap	Approx. Rs 1,330 crore	Micro-cap pharma
NSE Ticker	SAKARBIO	Sector: Specialty Pharmaceuticals

Screen the best stocks on the Univest Screener.

Sakar Healthcare Q4 FY26 Stellar Performance Analysis

Sakar Healthcare Q4 FY26 results represent a standout quarterly performance, with revenue growth of 41.52 percent, PAT growth of 91.32 percent, and the highest-ever operating margin of 36.91 percent. The operating margin expansion of 560 basis points from the previous quarter and from the year-ago period reflects Sakar Healthcare’s successful scaling of its specialty pharmaceutical products with improving pricing power and operating leverage. The PAT margin improvement to 15.50 percent from 11.46 percent year-on-year demonstrates that revenue growth is efficiently converting to bottom-line gains. Sakar Healthcare’s products span pharmaceutical formulations, nutraceuticals, and specialty health products.

The stock’s strong 93.53 percent one-year return has pushed it to a price-to-earnings ratio of approximately 41x, which investors should note when assessing entry points. Post Sakar Healthcare Q4 FY26 results, the sustainability of the 36.91 percent operating margin will be the key question, alongside management commentary on new product launches, regulatory approvals, and the revenue growth trajectory in FY27.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on Sakar Healthcare Q4 FY26 Results

What is Sakar Healthcare Q4 FY26 net profit?

Ans. Sakar Healthcare Q4 FY26 consolidated net profit is Rs 11.02 crore, a 91.32 percent year-on-year surge, with revenue up 41.52 percent to Rs 71.10 crore.

What was Sakar Healthcare Q4 FY26 operating margin?

Ans. Sakar Healthcare Q4 FY26 operating margin (excluding other income) was 36.91 percent, the highest in the company’s recent history, representing a 560 basis point expansion from the previous quarter.

How did the market react to Sakar Healthcare Q4 FY26?

Ans. Sakar Healthcare stock gained 4.94 percent to close at Rs 597.80 on May 13, 2026, reflecting positive investor response to the strong Q4 FY26 results and highest-ever operating margin.

Where can I track Sakar Healthcare live price?

Ans. Track Sakar Healthcare live price, analyst ratings, and Q4 FY26 earnings updates on the Univest Screener.

Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. All financial data cited is sourced from BSE/NSE exchange filings and verified news sources. Investments in securities are subject to market risk. Consult a SEBI-registered investment advisor before making any investment decision.